ReviewThorax2013
Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense?
Review in Thorax, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02892396 (Influence of Electronic Cigarettes in the Evaluation of the Inflammatory Response in Patients With a Diagnosis of COPD), which is not on this map. Cited by 49 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Influence of Electronic Cigarettes in the Evaluation of the Inflammatory Response in Patients With a Diagnosis of COPD
Who cites it
49 citing papers in PubMed, 3 syntheses or guidelines pooled it, 138 citations in OpenAlex.
- Does pulmonary rehabilitation address treatable traits? A systematic review.European respiratory review : an official journal of the European Respiratory Society · 2022Pooled it
- Pooled it
- Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis.International journal of chronic obstructive pulmonary disease · 2018Pooled it
- Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts.International journal of chronic obstructive pulmonary disease · 2016Trial
- Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled Trial.PloS one · 2015Trial
- Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.International journal of chronic obstructive pulmonary diseaseTrial
- Treatable traits approach for personalised management of sarcoidosis.BMJ open respiratory research · 2026Review
- Inflammatory discordance phenotype in COPD: Dissociation between neutrophil-to-lymphocyte ratio and conventional markers.PloS one · 2026Article
- Treatable traits in asthma associated with hospitalisations.ERJ open research · 2026Article
- COPD: the role of neutrophils in inflammation, pathophysiology, and as drug targets.Clinical science (London, England : 1979) · 2025Review
- Exploring Clinical Control of COPD: Insights From a Portuguese Outpatient Population.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025Article
- Review
- Hemoglobin as a Treatable Trait in COPD: A Retrospective Observational Cohort Study on Hemoglobin Levels and All-Cause Mortality from NHANES Data.International journal of chronic obstructive pulmonary disease · 2025Observational
- Clinical Benefits of Targeting Treatable Traits in Asthma and Chronic Obstructive Pulmonary Disease.Internal medicine (Tokyo, Japan) · 2025Review
- Integrating hot topics and implementation of treatable traits in asthma.The European respiratory journal · 2024Review
- Physical capacity and inactivity in obstructive airway diseases: a "can do, do do" analysis.ERJ open research · 2024Article
- First Report of the Prevalence at Baseline and after 1-Year Follow-Up of Treatable Traits in Interstitial Lung Diseases.Biomedicines · 2024Article
- The treatable traits of asthma in pregnancy: a clinical audit.ERJ open research · 2024Article
- Inflammatory profile of eosinophils in asthma-COPD overlap and eosinophilic COPD: a multi-omics study.Frontiers in immunology · 2024Article
- Walking the path of treatable traits in interstitial lung diseases.Respiratory research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe rising disease burden from chronic obstructive pulmonary disease (COPD) requires new approaches.
methodWe suggest an approach based around three elements: inflammometry and multidimensional assessment to identify therapeutic targets and case management to design and implement an individualised treatment programme based on these assessments. DISCUSSION: This tailored approach to treatment would maximise efficacy, limit cost and permit a better risk-benefit ratio of treatment. The advantages include the ability to add up the benefits of individual therapies leading to a cumulative therapeutic benefit that is greater than each individual therapy alone. We can now design a multifaceted inflammometry intervention for airway diseases based on targeting eosinophilic inflammation, non-eosinophilic pathways and systemic inflammation. COPD is a complex and challenging disease. The use of inflammometry and multidimensional assessment is necessary to identify relevant treatment targets and maximise the scope of therapy while limiting unnecessary use of drugs. An individualised programme of management can be designed and coordinated by using a case manager. This new approach may provide tangible benefits to people with COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.